What Did NAMS Actually Say?

In 2022, the North American Menopause Society (now called The Menopause Society) released an updated position statement on hormone therapy — and it made waves in women's health conversations across the board.

For many women in midlife, hormone therapy has felt like a topic surrounded by decades of conflicting headlines, changing recommendations, and general confusion. The 2022 NAMS statement offered a more nuanced view of the evidence: recognizing that for many women, particularly those in early menopause or the years close to it, the balance of benefits and considerations around hormone therapy looks different than older, broader-brush guidance suggested.

The statement covers a wide range of topics, including:

• How individual factors — including age, time since menopause, and personal health history — shape the conversation around hormone therapy
• The role hormone changes can play in quality of life during the menopause transition
• The importance of individualized discussions between women and their healthcare providers
• Why a one-size-fits-all approach to hormone therapy guidance doesn't serve most women well

If you've been trying to make sense of conflicting information about hormones and midlife health, reading the source document is worth your time. It's dense — it is a medical society position statement, after all — but it represents some of the most current, evidence-based thinking available.

Read the 2022 hormone therapy position statement of The North American Menopause Society

This article is for educational and general wellness purposes only. It is not medical advice and is not intended to diagnose, treat, cure, or prevent any disease. If you are noticing changes in your body or have questions about your health, please consult a knowledgeable healthcare provider.